Back to top
more

KalVista Pharmaceuticals (KALV)

(Delayed Data from NSDQ)

$11.78 USD

11.78
2,314,196

-0.27 (-2.24%)

Updated Jun 28, 2024 04:00 PM ET

After-Market: $11.75 -0.03 (-0.25%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (99 out of 249)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

1 item in cart

View Cart/Checkout

KalVista Pharmaceuticals, Inc. [KALV]

Reports for Purchase

Showing records 81 - 100 ( 106 total )

Company: KalVista Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 81

09/09/2019

Company Report

Pages: 6

FY1Q Update - With Two Shots on Goal by YE2019, We''re Liking Our Odds

Provider: Roth Capital Partners, Inc.

Analyst: JALLAH Z

Price: 25.00

Research Provided by a Third Party

Company: KalVista Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 82

09/06/2019

Company Report

Pages: 9

Pullback in KALV Creates a Buying Opportunity. Reiterate Buy and $30 PT.

Provider: Roth Capital Partners, Inc.

Analyst: JALLAH Z

Price: 25.00

Research Provided by a Third Party

Company: KalVista Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 83

09/06/2019

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: KalVista Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 84

08/07/2019

Company Report

Pages: 7

Invitation to Join Kalvista''s Management Call '-' August 19th as 12pm (ET)

Provider: Roth Capital Partners, Inc.

Analyst: JALLAH Z

Price: 25.00

Research Provided by a Third Party

Company: KalVista Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 85

08/07/2019

Daily Note

Pages: 5

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: KalVista Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 86

07/16/2019

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: KalVista Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 87

07/15/2019

Company Report

Pages: 9

FY2019 Update Highlights Several Near-Term, Value-Driving Catalysts

Provider: Roth Capital Partners, Inc.

Price: 25.00

Research Provided by a Third Party

Company: KalVista Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 88

07/12/2019

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: KalVista Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 89

07/12/2019

Company Report

Pages: 7

Board Chair Change Comes Ahead of Major Data Readouts in 2H19. Buy $30 PT

Provider: Roth Capital Partners, Inc.

Price: 25.00

Research Provided by a Third Party

Company: KalVista Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 90

05/28/2019

Company Report

Pages: 4

Transfer of Coverage; Maintain Buy Rating and $30PT

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: KalVista Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 91

05/15/2019

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: KalVista Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 92

05/15/2019

Company Report

Pages: 6

Kalvista Being Kalvista; Raising PT to $30

Provider: Roth Capital Partners, Inc.

Analyst: MARANGO J

Price: 25.00

Research Provided by a Third Party

Company: KalVista Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 93

03/04/2019

Daily Note

Pages: 2

California Dreamin? I: Biotech Stories To Keep An Eye On

Provider: Roth Capital Partners, Inc.

Analyst: MARANGO J

Price: 10.00

Research Provided by a Third Party

Company: KalVista Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 94

02/26/2019

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: KalVista Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 95

02/25/2019

Company Report

Pages: 6

HAE Program Marches On; Maintain Buy - Raising PT to $25

Provider: Roth Capital Partners, Inc.

Analyst: MARANGO J

Price: 25.00

Research Provided by a Third Party

Company: KalVista Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 96

01/31/2019

Industry Report

Pages: 4

Private Eye: New Entrant in HAE Prophylaxis

Provider: Roth Capital Partners, Inc.

Analyst: MARANGO J

Price: 10.00

Research Provided by a Third Party

Company: KalVista Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 97

01/02/2019

Industry Report

Pages: 2

Healthcare - It''s All About the Benjamins

Provider: Roth Capital Partners, Inc.

Analyst: MARANGO J

Price: 10.00

Research Provided by a Third Party

Company: KalVista Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 98

09/17/2018

Company Report

Pages: 6

Three Reasons Why We Like Kalvista

Provider: Roth Capital Partners, Inc.

Analyst: MARANGO J

Price: 25.00

Research Provided by a Third Party

Company: KalVista Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 99

09/17/2018

Daily Note

Pages: 3

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: KalVista Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 100

07/31/2018

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party